Drug Profile
Research programme: galectin inhibitors - La Jolla Pharmaceutical
Alternative Names: Galectin antagonists - La Jolla Pharmaceutical; Galectin-3 inhibitors - La Jolla Pharmaceutical; LJPC-201; LJPC-301Latest Information Update: 25 Aug 2022
Price :
$50
*
At a glance
- Originator La Jolla Pharmaceutical Company
- Class Monoclonal antibodies; Small molecules
- Mechanism of Action Galectin 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Heart failure; Hepatic fibrosis; Solid tumours
Most Recent Events
- 22 Aug 2022 La Jolla Pharmaceutical Company has been acquired by Innoviva
- 16 Jul 2016 No recent reports of development identified for research development in Heart-failure in USA (PO)
- 16 Jul 2016 No recent reports of development identified for research development in Hepatic-fibrosis in USA (PO)